Artículos por temáticas

Increased vocal intensity due to the Lombard effect in speakers with Parkinson's disease: simultaneous laryngeal and respiratory strategies.

Stathopoulos ET, Huber JE, Richardson K, Kamphaus J, DeCicco D, Darling M, Fulcher K, Sussman JE.

J Commun Disord. 2014 Mar-Apr;48:1-17. doi: 10.1016/j.jcomdis.2013.12.001.

Mutations in VPS26A are not a frequent cause of Parkinson's disease.

Koschmidder E, Mollenhauer B, Kasten M, Klein C, Lohmann K.

Neurobiol Aging. 2014 Jun;35(6):1512.e1-2. doi: 10.1016/j.neurobiolaging.2013.12.016.

Actigraphically-defined sleep disturbance in Parkinson's disease is associated with differential aspects of cognitive functioning.

Gunn DG, Naismith SL, Bolitho SJ, Lewis SJ.

J Clin Neurosci. 2014 Jul;21(7):1112-5. doi: 10.1016/j.jocn.2013.09.017.

Non-motor symptoms in Chinese Parkinson's disease patients.

Gan J, Zhou M, Chen W, Liu Z.

J Clin Neurosci. 2014 May;21(5):751-4. doi: 10.1016/j.jocn.2013.07.015.

Boosting response inhibition neural network with rTMS may improve dyskinesias in Parkinson's disease.

Obeso I, Strafella AP.

Brain Stimul. 2014 Mar-Apr;7(2):336-7. doi: 10.1016/j.brs.2013.12.004. No abstract available.

Peripheral expression of MAPK pathways in Alzheimer's and Parkinson's diseases.

Wang S, Zhang C, Sheng X, Zhang X, Wang B, Zhang G.

J Clin Neurosci. 2014 May;21(5):810-4. doi: 10.1016/j.jocn.2013.08.017.

Attention modulates step initiation postural adjustments in Parkinson freezers.

Tard C, Dujardin K, Bourriez JL, Destée A, Derambure P, Defebvre L, Delval A.

Parkinsonism Relat Disord. 2014 Mar;20(3):284-9. doi: 10.1016/j.parkreldis.2013.11.016.

Visual complaints and visual hallucinations in Parkinson's disease.

Urwyler P, Nef T, Killen A, Collerton D, Thomas A, Burn D, McKeith I, Mosimann UP.

Parkinsonism Relat Disord. 2014 Mar;20(3):318-22. doi: 10.1016/j.parkreldis.2013.12.009.

White matter changes in patients with Parkinson's disease carrying small CGG expansion FMR1 alleles: a pilot study.

Trost N, Cook M, Hammersley E, Bui MQ, Brotchie P, Burgess T, Slater H, Storey E, Loesch DZ.

Neurodegener Dis. 2014;14(2):67-76. doi: 10.1159/000356190.

Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.

Tan YY, Wu L, Zhao ZB, Wang Y, Xiao Q, Liu J, Wang G, Ma JF, Chen SD.

Parkinsonism Relat Disord. 2014 Mar;20(3):308-13. doi: 10.1016/j.parkreldis.2013.12.002.

Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease.

Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK.

Neurobiol Dis. 2014 Apr;64:79-87. doi: 10.1016/j.nbd.2013.12.011.

Aging risk factors and Parkinson's disease: contrasting roles of common dietary constituents.

Hipkiss AR.

Neurobiol Aging. 2014 Jun;35(6):1469-72. doi: 10.1016/j.neurobiolaging.2013.11.032. Review.

Serum melatonin is an alternative index of Parkinson's disease severity.

Lin L, Du Y, Yuan S, Shen J, Lin X, Zheng Z.

Brain Res. 2014 Feb 14;1547:43-8. doi: 10.1016/j.brainres.2013.12.021.

Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.

Bao XQ, Kong XC, Kong LB, Wu LY, Sun H, Zhang D.

Brain Res. 2014 Feb 14;1547:49-57. doi: 10.1016/j.brainres.2013.12.026.

Association between Glutathione S-transferase M1/Glutathione S-transferase T1 polymorphisms and Parkinson's disease: a meta-analysis.

Wang T, Wang B.

J Neurol Sci. 2014 Mar 15;338(1-2):65-70. doi: 10.1016/j.jns.2013.12.018.